Navigation Links
CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
Date:11/9/2008

l impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, or lopinavir/ritonavir.

Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who consume substantial quantities of alcohol.

CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg. Patients initiating CRESTOR therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose.

In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%).

Please see accompanying full Prescribing Information. If you have any questions concerning CRESTOR, please contact AstraZeneca at 1-800-237-8898. CRESTOR is a registered trademark of the AstraZeneca group of companies.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
4. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
5. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
6. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
7. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
8. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
9. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
10. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
11. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI ), ... and Drug Administration ("FDA"), has notified the Company that ... Drug ("IND") application before granting the Company permission to ... Dr. Chris Chapman , RCP,s President, commented, "We ... When we receive the agency,s official comments and/or recommendations, ...
(Date:7/11/2014)... , July 11, 2014 Research ... "Global Hypodermic Needles Market 2014-2018" report to their ... A hypodermic needle is a hollow needle commonly ... body or or to extract fluids from it. A ... or to inject substances that cannot be ingested. Hypodermic ...
(Date:7/11/2014)... On Thursday, July 10, 2014, the NASDAQ ... Average finished the day 0.42% lower at 16,915.07, and the ... broad based as eight out of ten sectors ended the ... ended the day at 711.88, down 0.02%, while the index ... initiated coverage on the following equities: Covidien PLC (NYSE: ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4
... 23, 2012 Event details: ... p.m. Renaissance Palm Springs Hotel ... , CA Ameritox(SM), the nation,s leader in ... emerging trends and technologies in medication monitoring at the American Academy of Pain ...
... , Inc. (Nasdaq: NXTM ), a leading ... of the Chronic Disease Research Group (CDRG) study which ... for daily, or more frequent, home hemodialysis, experienced a ... higher 3-year survival compared with that of patients treated ...
Cached Medicine Technology:Ameritox Provides Educational Support to Clinicians to Help Reduce Opioid Misuse, Abuse and Diversion 2Ameritox Provides Educational Support to Clinicians to Help Reduce Opioid Misuse, Abuse and Diversion 3Data Published in the Journal of the American Society of Nephrology Shows Daily Home Hemodialysis Patients with the NxStage System One Have Significantly Lower Risk of Mortality and Improved 3-Year Survival Versus Patients on Conventional Hemodialys 2Data Published in the Journal of the American Society of Nephrology Shows Daily Home Hemodialysis Patients with the NxStage System One Have Significantly Lower Risk of Mortality and Improved 3-Year Survival Versus Patients on Conventional Hemodialys 3Data Published in the Journal of the American Society of Nephrology Shows Daily Home Hemodialysis Patients with the NxStage System One Have Significantly Lower Risk of Mortality and Improved 3-Year Survival Versus Patients on Conventional Hemodialys 4
(Date:7/14/2014)... SUNDAY, July 13, 2014 (HealthDay News) -- Eye tests ... stages of Alzheimer,s disease, two new studies suggest. ... used a certain eye test found a significant association ... the eye and levels of the plaques in the ... Alzheimer,s disease. This type of eye test could ...
(Date:7/14/2014)... HealthDay Reporter MONDAY, July 14, 2014 ... may have bigger brains and sharper thinking skills than their ... connection between playing games such as puzzles, crosswords, cards and ... 60s. Researchers found that people who played those games ... memory and other mental functions. And, based on MRI scans, ...
(Date:7/14/2014)... Many people are unhappy with their ... to reduce a “double chin.” A new product ... to go under the knife. Jawflex is a double ... therefore tightening the skin in that area and reducing ... used for facial exercise, double chin elimination and sagging ...
(Date:7/14/2014)... July 14, 2014 Many diet plans often ... study by the School of Public Health at the University ... had a near-zero effect on weight loss. Now experts are ... with some form of portion control to trigger ... monitoring portions and controlling how much is consumed, simply by ...
(Date:7/14/2014)... Sometimes, thinking “inside the box” can ... its first product release, Joyboxx™ - The world’s only ... , Inventor and CEO, Deborah Semer began designing ... storage solution for their ‘toys’ after she realized no ... industry. , Semer met 30-year industry veteran Phyllis Heppenstall, ...
Breaking Medicine News(10 mins):Health News:Eye Tests Might Help ID Alzheimer's, Studies Suggest 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 3Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 3Health News:Passionate Playground launches Joyboxx 2Health News:Passionate Playground launches Joyboxx 3
... Win Patient Safety Protections, OAKLAND, Calif., ... University of California medical centers throughout the ... majority, the California Nurses Association,announced today. The ... as resolving long-standing issues of pension and ...
... serious trauma live, often with little visible damage, surgeons say ... of war in Iraq, there,s some relatively good medical ... are now surviving injuries that would have been fatal in ... The Journal of Craniofacial Surgery , the surgical and treatment ...
... Mich., March 24 Perrigo Company,(Nasdaq: PRGO ... CEO Joseph,C. Papa will present at the 12th ... March 25, at 2:05 p.m. (ET) at the,Grand ... Company is a leading global healthcare supplier that ...
... Fitness,Corporation (OTC Bulletin Board: HFIT) today announced that ... repurchase up to $2.5 million of the,company,s outstanding ... shares on the open market in amounts and ... with Securities and Exchange,Commission Rule 10b-18 and other ...
... urged to discuss risk factors with their doctors, ... long been known that,psoriasis, a chronic skin condition ... bleed, can have a significant negative impact on ... finding that,psoriasis, especially severe psoriasis, is linked with ...
... International,Corporation (Nasdaq: PRXL ) announced today it will ... Conference. James Winschel, Senior Vice,President and Chief Financial Officer ... a.m. ET on Thursday, March 27, 2008., A ... the,"Investor Relations Webcasts" section of PAREXEL,s web site at, ...
Cached Medicine News:Health News:UC RNs Overwhelmingly Approve New Contract 2Health News:UC RNs Overwhelmingly Approve New Contract 3Health News:Innovative Care Is Helping Iraq War's Injured Survive 2Health News:Innovative Care Is Helping Iraq War's Injured Survive 3Health News:Health Fitness Announces $2.5 Million Stock Repurchase Plan 2Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 2Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 3Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 4Health News:PAREXEL International to Present at Bank of America 2008 Smid Cap Conference 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: